Avelumab and Merkel Cell Carcinoma: Examining the Evidence on Risk and Causation
From General Health Information to Targeted Occupational Risk Assessment
The legacy of general health and science information has long emphasized broad public wellness, preventive care, and the communication of evidence-based findings to diverse audiences. This foundational approach has served to educate communities on a wide range of health determinants, from lifestyle factors to environmental influences, without delving into specific disease mechanisms. As industrial processes have evolved, however, the scope of health inquiry has necessarily narrowed to address more targeted questions arising from occupational and manufacturing contexts. Within this shift, the focus has turned to the potential health implications of exposure to substances used in production lines, including therapeutic agents repurposed for industrial applications. One such area of emerging interest involves the investigation of Avelumab, a monoclonal antibody employed in certain treatment protocols, and its possible association with Merkel Cell Carcinoma risk. Transitioning from the general health paradigm, the concern now centers on whether occupational exposure to Avelumab—through handling, manufacturing, or environmental release—may pose a carcinogenic risk to workers. This pivot reframes the discussion from broad health education to a specific, evidence-based examination of exposure hazards in mass production settings, setting the stage for a rigorous analysis of available studies without invoking mechanistic claims.
Avelumab: Mechanism and Approved Use in Merkel Cell Carcinoma
Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/;https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for this indication, and it is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).
Merkel Cell Carcinoma: Etiology and Epidemiology
Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus, with approximately 80% of cases caused by the human Merkel cell polyomavirus and the remaining 20% induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/35877101/;https://pubmed.ncbi.nlm.nih.gov/34445385/). The incidence rate of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab (anti-PD-L1) and pembrolizumab (anti-PD-1), offer durable responses and significant clinical benefit in advanced MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/;https://pubmed.ncbi.nlm.nih.gov/35877101/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy, and 50% of patients do not respond or develop immune-related adverse events due to diverse mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/35877101/;https://pubmed.ncbi.nlm.nih.gov/34445385/).
Therapeutic Role vs. Causation: What the Evidence Shows
The mechanistic pathway linking avelumab to Merkel cell carcinoma is primarily therapeutic rather than causative. Avelumab is used to treat MCC by blocking PD-L1, thereby enhancing T-cell responses against tumor cells (https://pubmed.ncbi.nlm.nih.gov/34445385/). The standard treatment of metastatic MCC is the use of anti-PD-1/-PD-L1 immune checkpoint inhibitors such as avelumab, which in comparison with conventional chemotherapy show better overall response rates and longer duration of responses in patients (https://pubmed.ncbi.nlm.nih.gov/34445385/). For patients who become refractory to avelumab, treatment options are limited. Studies have investigated the activity of ipilimumab plus nivolumab in avelumab-refractory MCC. In a multicenter study of the prospective skin cancer registry ADOREG, and in a retrospective study at three German sites, clinical and molecular data of patients with metastatic MCC refractory to avelumab and later treated with combined ipilimumab/nivolumab were collected (https://pubmed.ncbi.nlm.nih.gov/33439294/;https://pubmed.ncbi.nlm.nih.gov/36450381/). In one report, three out of five patients responded to combined ipilimumab/nivolumab according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another retrospective study noted that despite advances in systemic therapy, about 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).
Risk Context for Patients and Workers
Regarding causation-related considerations for affected patients, the evidence indicates that avelumab is not a cause of MCC but rather a treatment for it. The risk narrative centers on the adequacy of warnings about avelumab's efficacy and adverse effects. The drug is approved for metastatic MCC, and its use is associated with immune-related adverse events, which are documented in the literature (https://pubmed.ncbi.nlm.nih.gov/34445385/). The timeline between exposure and documented harm is relevant to patients who experience progression or adverse events while on avelumab therapy. For avelumab-refractory patients, efficient and safe treatment options are lacking, and the timeline from avelumab treatment to progression or adverse events can vary (https://pubmed.ncbi.nlm.nih.gov/33439294/). The evidence does not suggest that avelumab causes MCC; rather, it is a therapeutic agent for an existing condition. Warnings regarding avelumab should address its role as a treatment, its efficacy in a subset of patients, and the potential for lack of response or immune-related adverse events. In summary, avelumab is an immune checkpoint inhibitor approved for metastatic MCC, with evidence of efficacy in approximately one-third of chemotherapy-refractory patients. It is not a causative agent for MCC but a treatment. The risk for patients includes lack of response, progression, and immune-related adverse events. For those who become refractory, alternative therapies such as ipilimumab plus nivolumab may offer benefit, though data are limited to small studies.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.
Frequently Asked Questions
Does avelumab cause Merkel cell carcinoma?
No, avelumab is not a cause of Merkel cell carcinoma. It is a therapeutic agent used to treat metastatic Merkel cell carcinoma by blocking PD-L1 and enhancing T-cell responses against tumor cells (https://pubmed.ncbi.nlm.nih.gov/34445385/). The evidence indicates that avelumab is a treatment, not a causative factor.
What are the risks associated with avelumab treatment?
Risks include lack of response, disease progression, and immune-related adverse events. Approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy, and 50% do not respond or develop adverse events (https://pubmed.ncbi.nlm.nih.gov/35877101/;https://pubmed.ncbi.nlm.nih.gov/34445385/).
What is the evidence for avelumab's efficacy in Merkel cell carcinoma?
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.